Of all the monogenic forms of PD, LRRK2 and GBA mutations are the most advanced targets in several trials because they are considerably more common than the other monogenic forms of PD attributed to SNCA, PINK1, Parkin, and DJ1 mutations, for which it will be difficult to achieve an adequately powered clinical trial.22 This evidence concerns the gene GBA1 and Parkinson disease.